Setmelanotide vs TB-500
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Setmelanotide
Setmelanotide (Imcivree) is an FDA-approved MC4R agonist for chronic weight management in patients with obesity due to specific genetic conditions (POMC, PCSK1, or LEPR deficiency).
Full details →TB-500
Thymosin Beta-4 (TB-500) is a naturally occurring peptide present in almost all human and animal cells. It plays a crucial role in tissue repair and regeneration.
Full details →Side-by-Side Comparison
| Aspect | Setmelanotide | TB-500 |
|---|---|---|
| Mechanism | Selective agonist of melanocortin 4 receptors (MC4R) in the hypothalamus, restoring the satiety signaling pathway that is disrupted in certain genetic obesity syndromes. | TB-500 promotes cell migration and differentiation, regulates actin (a cell-building protein), and reduces inflammation. It supports the formation of new blood vessels and wound healing. |
| Typical Dosage | Adults: Start 2mg daily, titrate based on tolerability up to 3mg daily. Pediatrics (6+): Weight-based dosing starting at 1mg daily. | Research protocols typically use 2-2.5mg twice weekly during the loading phase, followed by maintenance dosing of 2mg every 2 weeks. |
| Administration | Subcutaneous injection once daily. Requires genetic testing to confirm eligible mutations before prescribing. | Administered via subcutaneous or intramuscular injection. Some protocols suggest injection near injury sites. |
| Side Effects | Injection site reactions, skin hyperpigmentation, spontaneous penile erections, depression, and suicidal ideation (boxed warning). GI effects less common than GLP-1s. | May cause temporary fatigue, headache, or localized irritation at injection sites. |
| Best For |